Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026

Viridian Therapeutics (VRDN) will report third quarter 2026 financial results before the market opens on November 4, 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial results before the market opens on Wednesday, November 4, 2026.

Management will host a live conference call on November 4, 2026 at 8:00 a.m. ET to discuss financial results and provide a business update. A webcast of the conference call can be accessed through the “Events & Presentations” page in the Investors section of the Viridian Therapeutics website. Following the live webcast, an archived version of the call will also be available in the Investors section of the Company’s website.

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes.

With an immediate focus in thyroid eye disease (TED), we developed Lumvoa^TM, a full IGF-1R antagonist approved by the U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261020707364/en/

Investors
Greg Rossino
grossino@viridiantherapeutics.com

Source: Viridian Therapeutics, Inc.

Key Terms

thyroid eye disease medical

An autoimmune condition where the body’s immune system causes inflammation and swelling in the tissues around the eyes, often producing pain, redness, bulging, double vision or vision loss. Investors care because the condition creates demand for drugs, surgeries and long-term care; clinical trial results, regulatory approvals, pricing and the number of affected patients can directly affect the revenue prospects and stock value of companies developing treatments.

igf-1r antagonist medical

A IGF-1R antagonist is a drug or biological agent that blocks the insulin-like growth factor 1 receptor (IGF-1R) on cells, preventing the receptor from receiving growth and survival signals. Because IGF-1R drives cell proliferation and resistance to cell death in some cancers and other diseases, blocking it is a targeted therapeutic strategy; clinical trial outcomes, safety data, and regulatory decisions for such agents can materially affect the value and prospects of companies developing them.

subcutaneous therapy medical

Subcutaneous therapy is a way of giving a medicine by injecting it just under the skin into the fatty layer, usually with a small syringe, pen, or pump. For investors, the delivery method matters because it can make treatments easier to use at home, improve patient adherence, reduce need for clinic visits, and influence manufacturing, pricing and market uptake—factors that affect sales and competitive advantage.